Danatlas Pharmaceuticals Co., Ltd
3 clinical trials · Sponsor
◉ Watch Danatlas Pharmaceuticals Co., Ltd
| Record | Firm | Date |
|---|---|---|
| A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer (NCT07652073) | Danatlas Pharmaceuticals Co., Ltd | 2026-06-15 |
| Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor (NCT06998173) | Danatlas Pharmaceuticals Co., Ltd | 2025-07-31 |
| A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway (NCT06614751) | Danatlas Pharmaceuticals Co., Ltd | 2024-11-01 |
Track Danatlas Pharmaceuticals Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.